Therapeutic Area: Oncology

T-cell tolerant fraction as a predictor of immune-related adverse events

Ostmeyer J, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Jared Ostmeyer 1, Jason Y Park 2, Mitchell S von Itzstein 3, David Hsiehchen 3,4, Farjana Fattah 4, Mary Gwin 3, Rodrigo Catalan 4, Shaheen Khan 2, Prithvi Raj 5, Edward K Wakeland 5, Yang Xie 1,4, David E Gerber 6,3,4; 1 Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4 Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5 Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6 Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA David.Gerber@utsouthwestern.edu.

Rigorous benchmarking of T-cell receptor repertoire profiling methods for cancer RNA sequencing

Peng K, et al.
Briefings in Bioinformatics
August 2023
Authors and Affiliates
Kerui Peng 1, Theodore S Nowicki 2,3, Katie Campbell 4, Mohammad Vahed 1, Dandan Peng 5, Yiting Meng 1, Anish Nagareddy 6, Yu-Ning Huang 1, Aaron Karlsberg 1, Zachary Miller 7, Jaqueline Brito 1, Brian Nadel 1,8, Victoria M Pak 9,10, Malak S Abedalthagafi 11,12, Amanda M Burkhardt 1, Houda Alachkar 1, Antoni Ribas 13, Serghei Mangul 1,5; 1 Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. 2 Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, Los Angeles, CA, USA. 3 Department of Microbiology, Immunology, & Molecular Genetics, University of California, Los Angeles, CA, USA. 4 Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA, USA. 5 Department of Quantitative and Computational Biology, USC Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA. 6 Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA. 7 Department of Pharmaceutical Sciences, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. 8 Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, CA, USA. 9 Emory Nell Hodgson School of Nursing, Emory University, Atlanta, GA, USA. 10 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 11 Department of Pathology & Laboratory Medicine, Emory University Hospital, Atlanta, GA, USA. 12 King Salman Center for Disability Research, Riyadh, Saudi Arabia. 13 Departments of Medicine (Hematology-Oncology), Surgery (Surgical Oncology) and Molecular & Medical Pharmacology, University of California, Los Angeles, CA, USA.

Health Consequences of Thymus Removal in Adults

Kooshesh KA, et al.
New England Journal of Medicine
August 2023
Authors and Affiliates
Kameron A Kooshesh 1, Brody H Foy 1, David B Sykes 1, Karin Gustafsson 1, David T Scadden 1; 1 From the Centers for Regenerative Medicine (K.A.K., D.B.S., K.G., D.T.S.) and Systems Biology (B.H.F.), Massachusetts General Hospital, the Harvard Stem Cell Institute (K.A.K., K.G., D.T.S.), the Department of Stem Cell and Regenerative Biology, Harvard University (K.A.K., K.G., D.T.S.), and Harvard Medical School (K.A.K., B.H.F., D.B.S., K.G., D.T.S.) - all in Boston.

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Hassan R, et al.
Nature Medicine
August 2023
immuneAccess
Authors and Affiliates
Raffit Hassan 1, Marcus Butler 2, Roisin E O'Cearbhaill 3, David Y Oh 4, Melissa Johnson 5, Kevin Zikaras 6, Munisha Smalley 6, Michael Ross 6, Janos L Tanyi 7, Azam Ghafoor 8, Nirali N Shah 9, Babak Saboury 10, Liang Cao 11, Alfonso Quintás-Cardama 12, David Hong 13; 1 Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. hassanr@mail.nih.gov. 2 Princess Margaret Cancer Centre, Toronto, ON, Canada. 3 Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA. 4 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 5 Sarah Cannon Cancer Center, Nashville, TN, USA. 6 TCR2 Therapeutics, Cambridge, MA, USA. 7 Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, USA. 8 Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 9 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 10 Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 11 Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 12 TCR2 Therapeutics, Cambridge, MA, USA. alfonso.quintas@tcr2.com. 13 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer

Jhawar SR, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Sachin R Jhawar 1, Shang-Jui Wang 1, Aditya Thandoni 2, Praveen K Bommareddy 3, Jenna H Newman 3, Amanda L Marzo 4, Timothy M Kuzel 4, Vineet Gupta 4, Jochen Reiser 4, Preston Daniels 4, Devora Schiff 3, Darrion Mitchell 1, Nicole R LeBoeuf 5,6, Christopher Simmons 7, Sharad Goyal 8, Ahmed Lasfar 3,9, Jose A Guevara-Patino 10, Bruce G Haffty 3, Howard L Kaufman 11, Ann W Silk 12,7, Andrew Zloza 13; 1 Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 2 Department of Orthopedic Surgery, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. 3 Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA. 4 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA. 5 Harvard Medical School, Boston, Massachusetts, USA. 6 Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. 7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 8 Department of Radiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA. 9 Department of Pharmacology and Toxicology, Ernest School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA. 10 Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA. 11 Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. 12 Harvard Medical School, Boston, Massachusetts, USA andrewzloza@gmail.com ann_silk@dfci.harvard.edu. 13 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA andrewzloza@gmail.com ann_silk@dfci.harvard.edu.

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

Dunlap GS, et al.
Nature Communications
August 2023
immuneAccess
Authors and Affiliates
Garrett S Dunlap 1,2, Daniel DiToro 2,3, Joel Henderson 4, Sujal I Shah 2,3, Mike Manos 5, Mariano Severgnini 5, Astrid Weins 2,3, Indira Guleria 2,3, Patrick A Ott 2,5,6,7,8, Naoka Murakami # 9,10, Deepak A Rao # 11,12; 1 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. 2 Harvard Medical School, Boston, MA, USA. 3 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 4 Department of Pathology, Boston Medical Center and Boston University, Boston, MA, USA. 5 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 7 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 8 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 9 Harvard Medical School, Boston, MA, USA. nmurakami1@bwh.harvard.edu. 10 Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA. nmurakami1@bwh.harvard.edu. 11 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. darao@bwh.harvard.edu. 12 Harvard Medical School, Boston, MA, USA. darao@bwh.harvard.edu.

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine

Tran CA, et al.
Journal of immunoTherapy of Cancer
August 2023
Authors and Affiliates
Christine A Tran 1, Kevin T Lynch 1, Max O Meneveau 1, Priya Katyal 2, Walter C Olson 1, Craig L Slingluff Jr 3,4; 1 Department of Surgery, University of Virginia Health, Charlottesville, Virginia, USA. 2 University of Virginia College and Graduate School of Arts and Sciences, Charlottesville, Virginia, USA. 3 Department of Surgery, University of Virginia Health, Charlottesville, Virginia, USA cls8h@virginia.edu. 4 Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, USA.

Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy

Osei-Hwedieh DO, et al.
JCI Insight
August 2023
Authors and Affiliates
David O Osei-Hwedieh 1, Abigail L Sedlacek 1, Luis Mena Hernandez 1, Archibald Agyekum Yamoah 2, Swati G Iyer 1, Kurt R Weiss 3, Robert J Binder 1; 1 Department of Immunology and. 2 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3 Department of Orthopaedic Surgery, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Cascini C, et al.
Journal of Experimental Medicine
August 2023
Authors and Affiliates
Caterina Cascini 1, Chiara Ratti 1, Laura Botti 1, Beatrice Parma 1, Valeria Cancila 2, Adriana Salvaggio 1, Cristina Meazza 3, Claudio Tripodo 2 4, Mario P Colombo 1, Claudia Chiodoni 5; 1 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. 2 Department of Health Science, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy. 3 Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. 4 IFOM, FIRC Institute of Molecular Oncology, Milan, Italy. 5 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. claudia.chiodoni@istitutotumori.mi.it.